STOCK TITAN

Checkpoint Therapeutics, Inc. - $CKPT STOCK NEWS

Welcome to our dedicated page for Checkpoint Therapeutics news (Ticker: $CKPT), a resource for investors and traders seeking the latest updates and insights on Checkpoint Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Checkpoint Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Checkpoint Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.43%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.7%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.2%
Tags
partnership
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.22%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.36%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.28%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.16%
Tags
conferences
Checkpoint Therapeutics, Inc.

Nasdaq:CKPT

CKPT Rankings

CKPT Stock Data

54.96M
28.74M
7.87%
14.53%
10.48%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
WALTHAM

About CKPT

checkpoint therapeutics, inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. the company's product candidates include ck-101 that in phase i clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and cosibelimab, a programmed death ligand-1 (pd-l1), which is in phase i clinical trial in patients with selected recurrent or metastatic cancers. it also develops ck-103, a small molecule inhibitor of bet bromodomains; and ck-302, a human agonistic antibody for oncology indications. checkpoint therapeutics, inc. has collaboration agreements with tg therapeutics, inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. the company was founded in 2014 and is headquartered in new york, new york. checkpoint therapeutics, inc. is a subsidiary of fortr